<DOC>
	<DOCNO>NCT00254137</DOCNO>
	<brief_summary>A randomized phase II-study evaluate safety efficacy capecitabine plus irinotecan plus cetuximab compare capecitabine plus oxaliplatin plus cetuximab first-line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Cap/Iri Plus Cetuximab Compared Cap/ox Plus Cetuximab Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm metastatic colorectal cancer . EGFreceptor test . No prior chemotherapy colorectal cancer ( except adjuvant chemotherapy interval ³ 6 month ) . No prior therapy topoisomerase1 inhibitor , prior therapy direct EGFpathway . No prior surgery ( except diagnostic biopsy ) radiation therapy 4 week start study treatment . Measurable disease ( diameter ³ 20mm , diameter ³ 10mm spiralCT ) . Male female patient ³ 18 year , £ 75 year . Karnofsky PS ³ 70 % . Life expectancy ³ 3 month . Effective contraception risk conception exists . Adequate bone marrow , liver renal function ( leucocytes ³3.000/µl , neutrophils ³1.500/µl , platelet ³100.000/µl , hemoglobin ³9g/dl , bilirubin £1,5x ULN , ASAT ALAT £3x ULN ( £5x ULN liver metastasis ) , serum creatinine £1,5x ULN ) . Written informed consent . Concurrent treatment colorectal cancer ( except study medication ) . EGFreceptor test possible . Known DPDdeficiency ( particular screen necessary ) . Known GilbertMeulengrachtSyndrome ( particular screen necessary ) . Known expected contraindication study medication . Participation study 30 day study entry . Prior myocardial infarction , severe renal insufficiency ( creatinine clearance £30ml/min ) . Previous malignancy ( except colorectal cancer , history basal cell carcinoma skin preinvasive carcinoma cervix adequate treatment sign disease 5 year ) . Known suspected cerebral metastasis . History inflammatory bowel disease . Symptomatic peritoneal carcinomatosis . Drug alcohol abuse . Lack adequate legal capacity . Breastfeeding pregnant woman . Concurrent medication Sorivudine analoga , anticoagulation Cumarine derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>